Optic neuritis is a rare autoimmune disease characterized by the inflammation of the optic nerve. The Food and Drug Administration (FDA) has granted Orphan Drug designation to TRE-515 for the ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...

Optic neuritis (ON) is an inflammation that damages your optic nerve. It can cause vision loss and pain when you move your eyes. As the inflammation goes away, your symptoms usually get better ...

Optic neuritis is a common symptom of multiple sclerosis (MS) that affects your eyes and vision. Learn more about the symptoms, causes, diagnosis, treatment, and complications of optic neuritis.

Optic neuritis needs prompt treatment, particularly when related to NMOSD and MOG, Lee said. A delay of even 4 days reduces the chance of regaining 20/20 vision by a factor of eight.

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpo ...

The Phase 2 ACUITY (Acute OptiC NeUrITis of DemYelinating Origin) trial was a randomized, double-blind, placebo-controlled, multi-center trial, designed to evaluate OCS-05 (2mg/kg/day or 3mg/kg ...

Oculis Holding AG. Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a ...

The Phase 2 ACUITY (Acute OptiC NeUrITis of DemYelinating Origin) trial was a randomized, double-blind, placebo-controlled, multi-center trial, designed to evaluate OCS-05 (2mg/kg/day or 3mg/kg/day) ...

ZUG, Switzerland, Jan. 06, 2025 (GLOBE NEWSWIRE) -- OCS-05 showed a favorable safety and tolerability profile compared to placeboAchieved statistically significant results on key secondary ...